Surmodics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Surmodics hat ein Gesamteigenkapital von $124.0M und eine Gesamtverschuldung von $29.5M, wodurch sich der Verschuldungsgrad auf 23.8% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $182.8M bzw. $58.9M. Surmodics Das EBIT des Unternehmens beträgt $18.5M, so dass der Zinsdeckungsgrad 10.1 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $40.9M.

Wichtige Informationen

23.8%

Verhältnis von Schulden zu Eigenkapital

US$29.48m

Verschuldung

Zinsdeckungsgrad	10.1x
Bargeld	US$40.94m
Eigenkapital	US$123.95m
Gesamtverbindlichkeiten	US$58.86m
Gesamtvermögen	US$182.81m

Jüngste Berichte zur Finanzlage

Recent updates

There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Jun 06

Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?

May 30

Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

May 02

We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

Sep 17

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Jun 26

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Jun 22

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

May 14

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Apr 17

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Feb 03

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Jan 08

Surmodics gets additional $125M in credit facility

Oct 17

Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M

Jul 27

Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Jul 22

Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

May 03

Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why

Feb 04

Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?

Dec 24

Estimating The Fair Value Of Surmodics, Inc. (NASDAQ:SRDX)

Aug 13

When Should You Buy Surmodics, Inc. (NASDAQ:SRDX)?

Jun 09

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: SRDXDie kurzfristigen Aktiva des Unternehmens ($84.3M) übersteigen seine kurzfristigen Passiva ($19.2M).

Langfristige Verbindlichkeiten: SRDXDie kurzfristigen Vermögenswerte des Unternehmens ($84.3M) übersteigen seine langfristigen Verbindlichkeiten ($39.7M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: SRDX über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: SRDXDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 23.8% gestiegen.

Schuldendeckung: SRDXDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (87.4%).

Zinsdeckung: Die Zinszahlungen für die Schulden von SRDX sind durch das EBIT gut gedeckt (10.1x coverage).

Surmodics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Recent updates

There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Price target decreased by 10% to US$52.33

GTCR LLC entered into a definitive agreement to acquire Surmodics, Inc. (NasdaqGS:SRDX) for approximately $620 million.

Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 24%

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2024

New major risk - Revenue and earnings growth

Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

Second quarter 2024 earnings released: EPS: US$0.017 (vs US$0.55 loss in 2Q 2023)

Surmodics, Inc. to Report Q2, 2024 Results on May 01, 2024

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Announces Successful Early Clinical Use of its Pounce LP Thrombectomy System

Surmodics, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Surmodics, Inc., Annual General Meeting, Feb 08, 2024

Insider exercised options and sold US$107k worth of stock

Surmodics, Inc. Announces 24-Month Data from the Swing Trial Presented At VEITHsymposium

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Surmodics, Inc. Announces Swing Trial 24-Month Data to Be Presented At Veith Symposium on November 15

Surmodics, Inc. Announces Launch of Preside Medical Device Coating Technology, Providing Lubricity and Durability to a Broader Range of Complex Device Applications

Surmodics, Inc. to Report Q4, 2023 Results on Nov 08, 2023

We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

Consensus revenue estimates increase by 12%

Price target increased by 8.7% to US$59.50

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year Ending September 30, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. to Report Q3, 2023 Results on Aug 02, 2023

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Surmodics, Inc.(NasdaqGS:SRDX) dropped from Russell 2000 Growth-Defensive Index

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Consensus revenue estimates increase by 11%

Surmodics, Inc. Receives FDA Approval for the SurVeil Drug-Coated Balloon

Surmodics Receives FDA 510(k) Clearance for Pounce LP Thrombectomy System

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Consensus EPS estimates upgraded to US$2.14 loss

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

Surmodics, Inc. to Report Q1, 2023 Results on Feb 06, 2023

Consensus EPS estimates fall by 20%

Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil Drug-Coated Balloon

Price target decreased to US$61.00

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Independent Director exercised options and sold US$64k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Director notifies of intention to sell stock

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Surmodics, Inc. Announces 24-Month Data from Its Transcend Clinical Trial At the Vascular InterVentional Advances

Surmodics, Inc. to Report Q4, 2022 Results on Nov 09, 2022

Surmodics, Inc. Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022

Surmodics gets additional $125M in credit facility

Surmodics, Inc. Announces 6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Surmodics, Inc. Updates Earnings Guidance for the Fiscal Year 2022

Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M

Insider exercised options and sold US$254k worth of stock

Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)

Surmodics, Inc. to Report Q3, 2022 Results on Jul 27, 2022

Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?

Price target increased to US$74.00

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surmodics, Inc. Revises Earnings Guidance for the Full Year Ended September 30, 2022

Insufficient new directors

Surmodics, Inc. to Report Q2, 2022 Results on Apr 27, 2022